Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report

Anaplastic lymphoma kinase (ALK) rearrangements are drivers of a subset of non‐small cell lung cancer (NSCLC). The rapid progression of ALK inhibitors has significantly prolonged the progression‐free survival of patients with ALK gene‐sensitive mutations. However, the response of patients with rare...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Kunyan, Nie, Ligong, Nong, Lin, Cheng, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201540/
https://www.ncbi.nlm.nih.gov/pubmed/33960639
http://dx.doi.org/10.1111/1759-7714.13983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201540/
https://www.ncbi.nlm.nih.gov/pubmed/33960639
http://dx.doi.org/10.1111/1759-7714.13983

Ejemplares similares